# I just got back home from two packed days at LSX2024 in London.

> I just got back from two packed days at LSX2024 in London, where I joined panels on pharma's path to launching digital health products and shared how QuantHealth will transform clinical trial design. Here are my key takeaways from the healthtech track.

URL: https://www.ch-healthtech.com/insights/i-just-got-back-home-two-packed-days-lsx2024-london
Markdown: https://www.ch-healthtech.com/insights/i-just-got-back-home-two-packed-days-lsx2024-london.md
Published: 2024-05-01
Updated: 2026-05-06
Author: Christian Hein
Tags: technology/artificial-intelligence, technology/digital-health, technology/in-silico-clinical-trials, industry/large-pharma, function/go-to-market, geography/europe

---


I just got back home from two packed days at LSX2024 in London.

I had the pleasure of being on two panels. In "Navigating Pharma's Path To Launching Digital Health Products", with amazing co-panelists Beth Wolff, Dominic James, and Dr. D. Martin Alexander Gershon, MD, JD, MPH, we discussed how the pharma industry is leveraging digital health and AI, and how these are being adopted (or not) by large and medium size pharmas, why pharma-pharma collaborations make a lot of sense, but are extremely hard to implement in real life, and how we see the emerging competition from big tech eventually disrupting the pharma workflow. Thank you to Samantha Peacock for hosting us.

In the Pharma Digital Leaders Forum hosted by Richard Cassidy, the panel shared tangible case studies and learnings. Gregoire Guillet described an amazing success of scaling a patient-enabling digital platform across a number of emerging markets, Beth Wolff shared her in-depth learnings from building a patient-facing digital solution for Lundbeck, and I discussed how QuantHealth will transform the way we design clinical trials. The discussion was very lively and interactive, thank you to everybody who participated.

Beyond reconnecting with friends, colleagues, and making a lot of amazing new connections, I'd like to share some key takeaways from the healthtech track at LSX.

- While health tech is clearly having a harder time than during the spectacular Covid boom, capital continues to flow into the sector, albeit more selective. As mentioned in my previous post following the MTIP conference earlier this year, further consolidation is inevitable (and already happening as we speak).

- As reimbursement opportunities for health tech solutions are slowly expanding across Europe with the recently launched pathway in France, the go-to-market and scaling pathways for AI, digital health, and DTx still is far from a straight path, given the large number of stakeholders (HCPs, providers, patients, cargivesthat need to be successfully onboarded and aligned. Direct-to-consumer out-of-pocket is working in some selected target segments, but in most EU markets is still very hard to pull off. And in the US, the employer target is starting to show signs of oversaturation.

- AI is clearly on everybody's mind, with GenAI getting all the limelight (though "old-school ML" is actually more relevant for many use cases), even if the actual implementation and adoption both within pharma and healthcare systems is still surprisingly slow. As a key takeaway, if the workflow isn't aligned, AI isn't going to get you anywhere, as adoption will quickly taper out. However, it is very clear that there isn't a single area of the pharma and health care value streams that won't be significantly impacted over the next 10 years